A user on finasteride, minoxidil, dermastamp, and Nizoral is seeing baby hairs and asks if it's regrowth. Another user confirms it is regrowth and encourages them to continue.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.
The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.
A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.
The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Applying minoxidil immediately after microneedling at 0.5mm can cause stinging and potential systemic absorption, so some users prefer to wait 12-24 hours. Others report no issues with immediate application, but caution is advised to avoid irritation and side effects.
The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.
Woman with AGA uses microneedling, minoxidil, spiro, and laser for hair loss. Experiences redness and tenderness for three days after microneedling with Dermapen M8, asks if it's normal and the correct speed setting.
A 26-year-old male shared his 3-month progress using Minoxidil and finasteride daily, microneedling weekly, and occasional vitamin D3. A commenter praised his impressive results.
A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.
Minoxidil helped with hairline regrowth, but stopping it led to hair loss, suggesting circulation issues. Dermarolling, collagen peptides, and oils like castor and rosemary are recommended for improving hair health.
OP is using oral 1mg finasteride, topical minoxidil, and microneedling twice a month at .75mm to regrow hair. They shared progress pictures over two months, noting they were bald for years before starting treatment.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.
A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.
The user experienced significant hair thinning and scalp irritation after three months of using topical finasteride. Suggestions include that shedding is normal before regrowth and switching to oral finasteride or addressing scalp inflammation might help.
The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
Optimal microneedling routine is 1.25mm once a week with Dr Pen 36 needles. Applying Minoxidil right after microneedling may increase systemic absorption risk.
The conversation discusses a hair loss flowchart for beginners, with mixed opinions on its effectiveness. Treatments mentioned include minoxidil, finasteride, dutasteride, microneedling, and vitamins.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
Dairy may contain DHT precursors that could affect hair loss and prostate health, with some users noting reduced hair shedding after eliminating dairy. Individual responses to dairy and DHT blockers vary, with some attributing hair health to diet changes and others seeing no impact.
A user's 18-month hairline progress using minoxidil, finasteride, Nizoral, microneedling, and scalp massage. They share their routine and discuss treatment effectiveness and photo order confusion.
The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.